From reviewing stop-loss contract language across a dozen carrier renewal packages in early 2026, the GLP-1 carve-out provisions vary widely enough to create meaningful cost differences for self-funded employers depending on which carrier they select. Some carriers exclude GLP-1 weight-loss claims entirely from the individual specific deductible. Others laser individual members already taking semaglutide or tirzepatide, setting custom attachment points that can run two to three times the standard specific deductible. A third group raises base attachment thresholds across the board to absorb anticipated GLP-1 cost escalation.

These are not minor contractual tweaks. For a self-funded employer running a 1,000-life plan with even modest GLP-1 utilization, the difference between a full carve-out and a standard inclusion can shift $300,000 to $500,000 in annual pharmacy risk from the stop-loss carrier back to the plan sponsor. Actuaries advising these sponsors need to model each contract structure separately, because the aggregate attachment analysis changes materially depending on which GLP-1 provisions apply.

This article breaks down the specific contract mechanisms carriers are using, quantifies the cost exposure at plan level, and provides a framework for comparing stop-loss proposals where GLP-1 language is the primary variable.

$27 PMPM
GLP-1 Cost Across All Covered Lives (Q1 2025)
21%
Share of Total Rx Spend From Five GLP-1 Drugs
49%
Employers Reporting $1M+ Stop-Loss Claims (2025)

The GLP-1 Cost Escalation That Forced the Contract Rewrite

The speed of GLP-1 cost growth explains why stop-loss carriers moved so aggressively at the 2026 renewal cycle. Willis Towers Watson data from the Rx Collaborative shows GLP-1 costs per member per month across all covered lives climbing from $1.50 in 2019 to $4.34 in 2022, then accelerating to $11 in 2023 and $24 in 2024. By Q1 2025, that figure reached $27.23 PMPM, representing an 18-fold increase over six years.

The share of total pharmacy spend tells a similar story. Five GLP-1 drugs now account for 21% of the Rx Collaborative's overall prescription cost after estimated rebates and discounts, up from 1% in 2020, according to WTW's April 2025 analysis. Evernorth's 2025 Pharmacy in Focus Report found that weight management medications were responsible for 46.8% of the total drug-spend increase in 2024, making GLP-1s the single largest pharmacy cost driver for the second consecutive year.

For individual plan members taking these medications, the per-user monthly costs are substantial. List prices run $900 to $1,400 per month for branded semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). After PBM rebates and discounts, the net plan cost typically falls to $400 to $700 per month, though an EBRI/BCBS analysis pegged the net figure as high as $766 per month for some plan configurations. Even at the lower end of that range, a single member on GLP-1 therapy for 12 months represents $4,800 to $8,400 in annual pharmacy spend before any associated medical claims for monitoring, lab work, or complications.

Patterns we have tracked across employer benefit plan data show these costs concentrating in a way that directly pressures stop-loss economics. Atria Insurance modeled a Minnesota school district where GLP-1 medications represented just 2% of prescriptions but consumed 56% of the entire pharmacy budget. Their analysis of a 1,000-employee organization showed that at 10% GLP-1 penetration (roughly 35 employees meeting medical criteria and filling prescriptions), annual GLP-1 spend reaches $504,000. At 20% penetration, that figure exceeds $1 million. With 35% of a typical workforce potentially eligible based on BMI alone, the upside risk for employers is enormous.

Three Contract Mechanisms Carriers Are Using

Stop-loss carriers have responded to this cost escalation with three distinct contractual mechanisms, often used in combination. Understanding the mechanics of each is essential for actuaries comparing renewal proposals.

Mechanism 1: GLP-1 Carve-Outs

The most aggressive approach excludes GLP-1 weight-loss claims entirely from counting toward the individual specific stop-loss attachment point. Under a standard specific stop-loss contract, once a member's claims exceed the specific deductible (commonly $100,000 to $250,000 for mid-market plans), the carrier reimburses the excess. A GLP-1 carve-out removes weight-loss-indication GLP-1 claims from the numerator of that calculation, meaning those costs never count toward breaching the attachment threshold.

The practical effect: 100% of GLP-1 weight-loss pharmacy exposure stays with the employer, regardless of how high it climbs. If a member has $180,000 in total claims but $60,000 of that is GLP-1 prescriptions for weight management, only $120,000 counts against a $150,000 specific deductible. The employer absorbs the full $180,000, where without the carve-out the stop-loss carrier would have reimbursed $30,000.

This matters most for high-utilizing members who combine GLP-1 therapy with other chronic conditions. A member taking Wegovy for obesity who also has diabetes management costs and cardiovascular monitoring could easily generate $200,000 or more in annual claims. Under a carve-out structure, the GLP-1 pharmacy component is stripped from the specific calculation even though it contributes meaningfully to total spend.

Critically, most carve-outs apply only to GLP-1 prescriptions written for the weight-loss indication (obesity, BMI-based criteria) and not to prescriptions for type 2 diabetes or cardiovascular risk reduction, which retain standard stop-loss treatment. This creates a diagnosis-dependent coverage gap that actuaries must model separately. A member prescribed semaglutide for diabetes is covered differently than one prescribed the same molecule at the same dose for obesity.

Mechanism 2: Laser Provisions

Lasers are not new to stop-loss underwriting, but their application to GLP-1 claimants represents an expansion of a tool traditionally reserved for transplant candidates, hemophilia patients, and other catastrophic-cost individuals. M3 Insurance defines a laser as "a specific limitation or exclusion applied to coverage for an individual claimant who has generated, or is expected to generate, exceptionally high medical and/or pharmacy costs."

In the GLP-1 context, carriers are identifying members already enrolled in GLP-1 therapy at renewal and setting individual-specific attachment thresholds substantially above the plan's standard specific deductible. Where the plan's base specific deductible might be $150,000, a lasered GLP-1 member might carry a $300,000 or $400,000 individual threshold. The employer absorbs all claims for that member up to the higher amount.

M3 Insurance's modeling provides a concrete comparison for a 300-life employer group with a $100,000 standard specific deductible and $700,000 annual stop-loss premium baseline. One high-cost dependent has expected annual costs of $350,000. Under a traditional laserable policy, the renewal increase might be 8% ($756,000 base premium) with a $150,000 laser liability, producing a worst-case total of $906,000. Under a "no new lasers" contract, the renewal increase could be 30% ($910,000 annual premium), with the excess priced into the rate permanently.

The laser approach has one structural advantage for employers: claimant persistence data suggests that a meaningful percentage of high-cost claimants terminate coverage within 6 to 18 months due to job changes, disability, or retirement. If a lasered GLP-1 member leaves the plan, the employer's excess liability disappears at the next renewal. The "no new lasers" premium load, by contrast, persists regardless of whether the specific claimant remains on the plan.

Mechanism 3: Raised Attachment Points

Some carriers have opted against member-specific provisions in favor of simply raising individual attachment points across the board to account for the new pharmacy cost baseline. Rather than carving out GLP-1 claims or lasering specific members, these carriers increase the standard specific deductible from, say, $100,000 to $125,000 or $150,000, effectively requiring the employer to absorb more risk on every member before stop-loss coverage activates.

This approach is less targeted but avoids the administrative complexity of tracking diagnosis-specific carve-outs or member-level lasers. For actuaries, the modeling is straightforward: the higher deductible reduces claim frequency above the attachment point, lowering expected carrier reimbursements and shifting that expected cost to the employer's retained risk layer.

Voya's 2025 stop-loss paid claims analysis, covering 2.2 million employees, quantifies how quickly claimants are breaching attachment thresholds. Claims incidence surged from 23.8 to 32.5 claims per 10,000 employees, approximately 9.8 high-cost claims annually for a 3,000-employee population equating to roughly $4.6 million in estimated expenses. Growth in individuals exceeding specific attachment points has been accelerating at every threshold level: 8.1% annual growth at $100,000, 10.9% at $150,000 and $250,000, 13.2% at $500,000, and 15.4% at $750,000.

The fastest growth at the highest thresholds suggests that raising attachment points alone may not be sufficient to protect carriers from the tail risk GLP-1 costs create when combined with other high-cost conditions.

The Stop-Loss Market Context: Premium Trends and Claims Severity

These GLP-1-specific contract changes are occurring within a broader stop-loss market that is already under claims pressure. The Aegis Risk 2025 Medical Stop-Loss Premium Survey, covering 1,268 plan sponsors representing 1.2 million employees and $1.2 billion in annual stop-loss premium, found single-year premium increases of 8.8% to 10% in 2025, with longer-term premium growth running 9.9% to 12.1%.

The most striking finding: 49% of survey respondents reported stop-loss claims exceeding $1 million in 2025, up from 23% in 2024. The share reporting claims exceeding $2 million reached 16%. Major carriers including Cigna, Voya, and Sun Life experienced what the survey characterized as "rough" claims experience in Q4 2024, driving anticipated higher rate increases for the 2026 renewal cycle.

Monthly stop-loss premiums vary substantially by deductible level, with the Aegis survey reporting $229.40 per covered employee at a $100,000 deductible, $50.96 at $500,000, and $17.69 at $1 million. For mid-market employers in the $100,000 to $250,000 deductible range where GLP-1 costs are most likely to interact with the specific attachment point, the premium impact of GLP-1 contract language is proportionally significant.

Pharmacy costs are driving the broader trend. Evernorth data shows traditional drug spending annual growth accelerating from 2.1% in 2021 to 12.8% in 2024. The GLP-1 net trend increase ran 210.2% in 2023 and 148.7% in 2024. Employers are anticipating 11% to 12% increases in pharmacy costs heading into 2026. Pharmacy now represents 24% of total health care dollars, up from historical levels in the high teens, and that share continues growing as GLP-1 utilization expands.

An EBRI study cited by BCBS modeled the premium impact of broad GLP-1 coverage across different scenarios. With broad eligibility and perfect adherence, the projected premium increase was 13.8%. With real-world adherence patterns factored in, that dropped to 10.4%. Narrow eligibility criteria with perfect adherence produced an 8.1% increase, while narrow eligibility with real-world adherence yielded 6.1%. Cost-sharing measures such as $90 copays reduced these figures by only 1 to 2 percentage points, suggesting that copay-based demand management has limited effectiveness for this drug category.

Employer Coverage Trends: The Demand Side of the Equation

While stop-loss carriers are tightening terms, employer demand for GLP-1 coverage continues growing, creating a strategic tension that self-funded plan actuaries must quantify. The Business Group on Health's 2026 employer survey found that 48% of employers now cover GLP-1s for weight loss, with 89% of those planning to continue coverage over the next one to two years. Among larger employers, 90% plan to continue; among mid-market employers, 86%.

The Peterson-KFF Health System Tracker provides granular data by employer size. Coverage of GLP-1s for weight loss among firms with 5,000 or more workers jumped from 28% in 2024 to 43% in 2025, a 54% year-over-year increase. Mid-sized firms (1,000 to 4,999 workers) stand at 30% coverage, and smaller firms (200 to 999 workers) at 16%. WTW's survey found 57% of respondents providing coverage for GLP-1 obesity medications.

Utilization is outpacing expectations. The Business Group on Health found 79% of employers currently seeing increased utilization of obesity medications, with another 15% anticipating increases. Peterson-KFF data shows 59% of firms with 5,000 or more workers reporting higher-than-expected GLP-1 use. The spending impact is pronounced: 66% of large firms report GLP-1 coverage has had a "significant" impact on prescription drug spending. Multiple employers documented 30% annual cost increases, with one organization reporting that GLP-1 drugs jumped from ranking #32 to #1 in pharmacy spending after coverage was added.

Employers are responding with clinical management requirements. Peterson-KFF found 34% of firms covering GLP-1s now require lifestyle or clinical support programs before approval, up from 10% in 2024. About 38% require participation in lifestyle behavior programs. Self-funded employers are also restructuring their PBM relationships: 49% now carve out pharmacy benefits with a standalone PBM, up from 27% in 2025, partly to gain more granular control over GLP-1 formulary management and rebate transparency.

The Talent Retention Bind

Compounding the coverage decision is the role GLP-1 access plays in employee recruitment and retention. HR Executive reporting found that nearly one-third (29%) of employees would switch employers to gain access to GLP-1 coverage. More than one in four employees prefer organizations offering these drugs. Among Gen Z workers, 35% believe GLP-1 medications improve job satisfaction.

This creates a bind that goes beyond actuarial cost modeling. Employers who drop or restrict GLP-1 coverage face potential talent attrition in a tight labor market. Employers who maintain broad coverage face stop-loss renewal terms that shift substantial risk back to the plan. The tension is especially acute for mid-market self-funded employers (500 to 3,000 lives) that lack the bargaining power of large national accounts but compete for the same talent pool.

The coverage retreat is already visible in some segments. NPR reported in April 2026 that 12 million people lost coverage for Zepbound and 12 million for Wegovy between 2025 and 2026 as coverage pulled back across employer and state plans. BCBS Massachusetts stopped covering GLP-1s for weight loss effective January 1, 2026, after its five GLP-1 drug companies accounted for 20% of total pharmacy spend and the insurer recorded a $400 million operating loss in 2024. BCBSMA's CFO cited costs "growing at the fastest rate in more than a decade," with GLP-1 spending forecasted to approach $1 billion in 2026 absent the exclusion. Health systems including Allina Health, RWJBarnabas, Ascension, and Hennepin Healthcare have discontinued GLP-1 weight-loss coverage for their own employees.

Mercer's 2026 analysis adds a sobering data point on long-term utilization: only 1 in 12 members remain on a GLP-1 drug for obesity at three years, based on Prime Therapeutics research. More than 50% of patients stop treatment within 12 months, with nearly two-thirds discontinuing before reaching the 12-week mark and over 40% stopping after just four weeks. This discontinuation pattern complicates the ROI case for employers and, from an actuarial standpoint, makes the per-member cost projection highly dependent on assumed persistence rates.

Actuarial Modeling Framework for Stop-Loss GLP-1 Provisions

For actuaries advising self-funded plan sponsors at renewal, the variation in GLP-1 contract language requires a structured comparison framework. Evaluating proposals from carriers with different GLP-1 provisions on an apples-to-apples basis demands several modeling adjustments that go beyond standard stop-loss premium comparison.

Step 1: Identify Current GLP-1 Exposure

Pull pharmacy claims data for all members currently filling GLP-1 prescriptions. Separate by indication: type 2 diabetes, cardiovascular risk reduction, and weight loss. Most carve-outs and lasers apply only to the weight-loss indication, so the split is essential. Quantify the annual run-rate cost per member and aggregate across the plan.

Step 2: Model Each Carrier's Contract Structure

For each renewal proposal, model the specific stop-loss calculation under the carrier's GLP-1 provisions. Build three scenarios:

Contract Type GLP-1 Weight-Loss Claims Treatment Risk to Employer
Standard inclusion Count toward specific deductible like any other claim Lowest retained risk; carrier absorbs GLP-1 costs above attachment point
Full carve-out Excluded entirely from specific deductible calculation Highest retained risk; 100% of GLP-1 weight-loss spend stays with employer
Laser on current users Named members get elevated individual thresholds Moderate retained risk; concentrated on identified members
Raised attachment point Higher base specific deductible for all members Moderate retained risk; spread across full population

Step 3: Quantify the Retained Risk Delta

Calculate the expected dollar value of GLP-1 claims that would be reimbursed under a standard inclusion contract but fall below the threshold under each alternative structure. This is the retained risk delta and represents the true cost of the GLP-1 contract provision to the employer, separate from the quoted premium.

For a concrete example: a 1,000-life plan with a $150,000 specific deductible, 25 members on GLP-1 therapy for weight loss at an average annual cost of $7,200 per member ($600/month net of rebates), and five of those members also carrying chronic conditions pushing total claims near or above the attachment point. Under standard inclusion, three members might breach $150,000, generating $120,000 in carrier reimbursements. Under a full carve-out, those three members' GLP-1 costs no longer count, and none breach the threshold, so the employer absorbs the full $120,000 plus the underlying GLP-1 spend.

Step 4: Adjust for Utilization Trend

Current GLP-1 utilization is not static. Model forward utilization at multiple penetration rates. Peterson-KFF data showing 34.2 million privately insured adults qualifying medically for GLP-1 drugs based on BMI alone suggests the eligible population far exceeds current uptake. Even conservative growth assumptions (10% to 15% annual utilization increase) can materially change the retained risk calculation over a two- to three-year projection period.

Step 5: Evaluate Aggregate Stop-Loss Interaction

GLP-1 carve-outs affect the aggregate attachment calculation as well as the specific. If GLP-1 claims are excluded from specific reimbursements, they remain in the plan's total claims but produce no offsetting carrier payments. This increases net plan cost and, depending on aggregate corridor width, can push the plan closer to the aggregate attachment point. Model the aggregate interaction explicitly, because a plan that appears adequately protected on the specific side may be underprotected on the aggregate side once GLP-1 carve-out effects are included.

Clinical Management Strategies and Their Actuarial Impact

Employers and their actuaries are deploying clinical management programs alongside stop-loss negotiation to control GLP-1 cost exposure. Mercer's 2026 survey found 77% of large employers (500 or more employees) rate managing GLP-1 costs as "extremely or very important." The most common approaches include prior authorization with diagnosis documentation, step therapy requirements, participation mandates for lifestyle behavior programs, and quantity limits.

From tracking these programs across employer renewals, the actuarial impact varies significantly by design. Prior authorization alone reduces new starts but has limited effect on ongoing utilization from existing users. Step therapy requirements, where members must try lower-cost interventions before GLP-1 approval, can reduce initial uptake by 15% to 25% but face pushback from employees who view them as barriers to care. Programs that combine prior authorization with mandatory lifestyle counseling, nutritional support, and activity monitoring show the strongest utilization management results but are more expensive to administer.

CRC Benefits' broker guidance for 2026 recommends what they call "exclusion with exceptions," covering GLP-1s for FDA-approved indications such as cardiovascular risk reduction while excluding general weight management use. CRC characterizes this as "the most common and arguably the most sustainable for 2026" approach, because it balances clinical evidence with financial reality and gives employers "a documented, defensible policy." Implementation requires prior authorization with diagnosis and physician documentation aligned to FDA-approved indications, coverage contingent on structured program participation, and compliance with IRS guidance for HSA/FSA/HRA eligibility.

The discontinuation data adds another dimension to the clinical management calculus. With more than 50% of GLP-1 patients stopping treatment within 12 months and nearly two-thirds discontinuing before reaching 12 weeks, the cost projection for any given cohort of new GLP-1 users is heavily front-loaded. Actuaries should model persistence curves rather than assuming steady-state annual utilization when projecting stop-loss interaction effects.

Legal and Compliance Considerations

Self-funded plan sponsors and their actuaries should be aware of emerging legal risks associated with GLP-1 coverage decisions. NFP's analysis of discrimination considerations highlights that while courts generally hold obesity alone does not qualify as a disability under the ADA (obesity must stem from an underlying physiological disorder that substantially limits a major life activity), uniform exclusions across overweight and obese participants appear permissible. Disparate impact claims remain theoretically possible but have not yet produced significant case law in the GLP-1 context.

A more immediate compliance question involves the Mental Health Parity and Addiction Equity Act (MHPAEA). Clinical evidence suggesting GLP-1 effectiveness for substance use disorders creates a potential parity issue if coverage is strictly limited to medical conditions such as diabetes, heart disease, and obesity. Plans that cover GLP-1s for metabolic indications but deny them for substance use treatment may face scrutiny under the NQTL comparative analysis framework that took full effect in January 2026.

The oral GLP-1 pipeline adds another variable. Mercer notes that two oral GLP-1 options are expected within 12 to 18 months, which could change the cost dynamics substantially. Generic alternatives, however, remain more than five years away. Actuaries projecting multi-year stop-loss cost trajectories should scenario-test both the oral GLP-1 pricing impact and the longer-term generic entry timeline.

Why This Matters for Actuaries

The stop-loss GLP-1 contract rewrite represents a structural shift in how pharmacy risk is allocated between self-funded employers and their stop-loss carriers. This is not a temporary market dislocation that will self-correct at the next renewal cycle. GLP-1 costs are growing at triple-digit rates, employer coverage is expanding despite carrier pushback, and the eligible population (57 million privately insured adults by EBRI's estimate) dwarfs current utilization.

For consulting actuaries advising self-funded plans, the immediate action items are concrete. First, read the GLP-1 contract language in every stop-loss proposal word by word. The difference between "excludes GLP-1 claims for weight management from the specific deductible" and "does not reimburse GLP-1 claims for weight management above the specific deductible" is subtle but financially meaningful. Second, build parallel stop-loss models with and without GLP-1 carve-out effects, including the aggregate interaction. Third, stress-test utilization assumptions. A plan with 3% GLP-1 penetration today could reach 8% to 10% within two years based on current employer coverage expansion trends.

For pricing actuaries at stop-loss carriers, the challenge is equally acute. The 2025 claims experience, with 49% of plans reporting million-dollar-plus claims, suggests that current pricing may not adequately reflect GLP-1 tail risk. The carve-out and laser provisions are rational underwriting responses, but they also concentrate anti-selection risk: employers with low GLP-1 utilization will shop for carriers that include GLP-1 coverage at standard terms, while employers with high utilization will gravitate toward carriers offering no-laser contracts at higher premiums. The resulting adverse selection spiral is a familiar actuarial problem in a new context.

The 2026 renewal season is producing real contract data on how carriers price GLP-1 risk at the individual stop-loss level. Actuaries who build comparative models now will be positioned to advise clients through what is shaping up to be the most significant pharmacy-driven repricing of stop-loss coverage in at least a decade.

Further Reading

Sources